Table 5.

Safety data from clinical trials of immune checkpoint inhibitors in advanced HCC [89].

TOXICITIES.	Nivolumab.	Pembrolizumab.	Atezolizumab + Bevacizumab.	Pembrolizumab + Lenvatinib.	Nivolumab + Ipilimumab.
Grade ≥ 3 AEs.	22%.	46.3%.	56.5%.	67% (including three grade 5 events).	37%.
Discontinuation rate for AEs.	4%.	17.2%.	15.5%.	Not reported.	2–18%.

AE = adverse event; HCC = Hepatocellular carcinoma.